Latest & greatest articles for rosuvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rosuvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rosuvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rosuvastatin

21. Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population Insights From the ARIC (Atherosclerosis Risk in Communities) Study Full Text available with Trip Pro

Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population Insights From the ARIC (Atherosclerosis Risk in Communities) Study The purpose of this study is to describe the proportion of "JUPITER-eligible" (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) individuals and clinical outcomes of individuals based on high-sensitivity C-reactive protein (hs

2010 EvidenceUpdates

22. Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein

Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein MacDonald (...) GP Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of rosuvastatin for the primary prevention of cardiovascular events in patients with different Framingham Risk Scores (FRSs

2010 NHS Economic Evaluation Database.

23. JUPITER randomised controlled trial: Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women as in men

JUPITER randomised controlled trial: Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women as in men Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women as in men | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women as in men Article Text Therapeutics JUPITER

2010 Evidence-Based Medicine

24. Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of randomised controlled trials

Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

25. An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial

An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 NHS Economic Evaluation Database.

26. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial Full Text available with Trip Pro

Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial This ancillary analysis of the GISSI-HF database aims at assessing the effect of rosuvastatin on the occurrence of atrial fibrillation (AF) in patients with chronic heart failure (HF) who were not in AF at study entry.GISSI-HF was a double-blind, placebo-controlled trial testing n-3 PUFA and rosuvastatin vs. corresponding placebos in patients with chronic HF. Atrial fibrillation occurrence (...) was defined as the presence of AF in the electrocardiogram (ECG) performed at each visit during the trial or AF as a cause of worsening HF or hospital admission or as an event during hospitalization. Among the 3690 patients (80.7%) without AF on their baseline ECG, 15.0% developed AF during a median follow-up period of 3.7 years, 258 randomized to rosuvastatin (13.9%) vs. 294 allocated to placebo (16.0%). Although the difference was not significant at unadjusted analysis (P = 0.097) and multivariable

2009 EvidenceUpdates Controlled trial quality: predicted high

27. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event Full Text available with Trip Pro

Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event In addition to inhibiting cholesterol biosynthesis, statins also inhibit the formation of isoprenoid intermediates, which are required for the activation of the Rho/Rho kinase (ROCK) pathway. Increased ROCK activity has been implicated in causing endothelial dysfunction and atherosclerosis. However, it is not known whether statins, at doses used (...) to lower cholesterol levels, inhibit ROCK activity in humans with atherosclerosis. Furthermore, it is not known whether lipophilic and hydrophilic statins differ in their ability to inhibit ROCK activity. Accordingly, we enrolled 30 men with stable atherosclerosis (low-density lipoprotein [LDL] > or =100 mg/dL) in a randomized, double-blind study comparing equivalent LDL-lowering doses of a hydrophilic statin (rosuvastatin 10 mg once a day) with a lipophilic statin (atorvastatin 40 mg once a day

2009 EvidenceUpdates Controlled trial quality: uncertain

28. Rosuvastatin prevented major cardiovascular events in people with elevated C-reactive protein

Rosuvastatin prevented major cardiovascular events in people with elevated C-reactive protein Rosuvastatin prevented major cardiovascular events in people with elevated C-reactive protein | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Rosuvastatin prevented major cardiovascular events in people with elevated C-reactive protein Article Text Therapeutics Rosuvastatin prevented major cardiovascular events in people with elevated C

2009 Evidence-Based Medicine

29. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. Full Text available with Trip Pro

A randomized trial of rosuvastatin in the prevention of venous thromboembolism. Controversy persists regarding the extent of shared pathways between arterial and venous thrombosis and whether treatments of known efficacy for one disease process have consistent benefits for the other. Observational studies have yielded variable estimates of the effect of statin therapy on the risk of venous thromboembolism, and evidence from randomized trials is lacking.We randomly assigned 17,802 apparently (...) healthy men and women with both low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to receive rosuvastatin, 20 mg per day, or placebo. We followed participants for the first occurrence of pulmonary embolism or deep-vein thrombosis and performed analyses of the data on an intention-to-treat basis.During a median follow-up period of 1.9 years (maximum, 5.0), symptomatic

2009 NEJM Controlled trial quality: predicted high

30. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. (Abstract)

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Statins lower high-sensitivity C-reactive protein (hsCRP) and cholesterol concentrations, and hypothesis generating analyses suggest that clinical outcomes improve in patients given statins who achieve hsCRP concentrations less than 2 mg/L in addition to LDL cholesterol less than 1.8 mmol/L (<70 mg/dL). However, the benefit of lowering (...) both LDL cholesterol and hsCRP after the start of statin therapy is controversial. We prospectively tested this hypothesis.In an analysis of 15 548 initially healthy men and women participating in the JUPITER trial (87% of full cohort), we prospectively assessed the effects of rosuvastatin 20 mg versus placebo on rates of non-fatal myocardial infarction, non-fatal stroke, admission for unstable angina, arterial revascularisation, or cardiovascular death (prespecified endpoints) during a maximum

2009 Lancet Controlled trial quality: predicted high

31. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. Full Text available with Trip Pro

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. Statins reduce the incidence of cardiovascular events in patients at high cardiovascular risk. However, a benefit of statins in such patients who are undergoing hemodialysis has not been proved.We conducted an international, multicenter, randomized, double-blind, prospective trial involving 2776 patients, 50 to 80 years of age, who were undergoing maintenance hemodialysis. We randomly assigned patients to receive (...) rosuvastatin, 10 mg daily, or placebo. The combined primary end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary end points included death from all causes and individual cardiac and vascular events.After 3 months, the mean reduction in low-density lipoprotein (LDL) cholesterol levels was 43% in patients receiving rosuvastatin, from a mean baseline level of 100 mg per deciliter (2.6 mmol per liter). During a median follow-up period of 3.8 years, 396

2009 NEJM Controlled trial quality: predicted high

32. Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice

Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice Gandhi SK, Jarbrink K, Fox KM, Brandrup-Wognsen G CRD summary This review concluded that compared with other statins there was strong and consistent evidence (...) to demonstrate the effectiveness of rosuvastatin in reducing low-density lipoprotein cholesterol (LDL-C) and LDL-C goals in usual care settings. These conclusions should be interpreted with caution given a possibility of publication bias, insufficient data and limited methodological rigour of the included studies. Authors' objectives To assess the effectiveness of rosuvastatin for the treatment of hypercholesterolaemia in the usual-care setting. Searching MEDLINE and EMBASE were searched from January 2003

2009 DARE.

33. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. (Abstract)

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Large observational studies, small prospective studies and post-hoc analyses of randomised clinical trials have suggested that statins could be beneficial in patients with chronic heart failure. However, previous studies have been methodologically weak. We investigated the efficacy and safety of the statin rosuvastatin in patients with heart failure.We (...) undertook a randomised, double-blind, placebo-controlled trial in 326 cardiology and 31 internal medicine centres in Italy. We enrolled patients aged 18 years or older with chronic heart failure of New York Heart Association class II-IV, irrespective of cause and left ventricular ejection fraction, and randomly assigned them to rosuvastatin 10 mg daily (n=2285) or placebo (n=2289) by a concealed, computerised telephone randomisation system. Patients were followed up for a median of 3.9 years (IQR 3.0

2008 Lancet Controlled trial quality: predicted high

34. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Full Text available with Trip Pro

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment.We randomly assigned 17,802 apparently healthy men (...) and women with low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to rosuvastatin, 20 mg daily, or placebo and followed them for the occurrence of the combined primary end point of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes.The trial was stopped after a median follow-up of 1.9 years

2008 NEJM Controlled trial quality: predicted high

35. Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal

Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal Pinto C G, Carrageta M O, Miguel L S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the clinical and economic impact of rosuvastatin (ROS) versus other statins in the treatment of hypercholesterolaemia and prevention of ischaemic heart disease, in untreated individuals over 35 years of age with previously untreated hypercholesterolaemia. The authors concluded that ROS was a cost-effective strategy in the Portuguese setting. The study

2008 NHS Economic Evaluation Database.

36. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of rosuvastatin in comparison with atorvastatin, simvastatin, and pravastatin for managing lipid parameters in patients with hypercholesterolaemia. The authors

2008 NHS Economic Evaluation Database.

37. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. Full Text available with Trip Pro

Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. Atherosclerosis is often advanced before symptoms appear and it is not clear whether treatment is beneficial in middle-aged individuals with a low Framingham risk score (FRS) and mild to moderate subclinical atherosclerosis.To assess whether statin therapy could slow progression and/or cause regression of carotid intima-media thickness (CIMT) over 2 (...) years.Randomized, double-blind, placebo-controlled study (Measuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin [METEOR]) of 984 individuals, with either age (mean, 57 years) as the only coronary heart disease risk factor or a 10-year FRS of less than 10%, modest CIMT thickening (1.2-<3.5 mm), and elevated LDL cholesterol (mean, 154 mg/dL); conducted at 61 primary care centers in the United States and Europe between August 2002 and May 2006.Participants received either a 40-mg dose

2007 JAMA Controlled trial quality: predicted high

38. Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario

Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario Araujo D V, Bahia L (...) , Souza C P, Pavao A L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the cost-effectiveness of rosuvastatin versus atorvastatin for lowering low-density lipoprotein-cholesterol and avoiding future cardiovascular

2007 NHS Economic Evaluation Database.

39. Rosuvastatin in older patients with systolic heart failure. (Abstract)

Rosuvastatin in older patients with systolic heart failure. Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients.A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome (...) was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations.As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median

2007 NEJM Controlled trial quality: predicted high

40. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK

Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Davies A, Hutton J, O'Donnell J, Kingslake S Record Status This is a critical abstract (...) rosuvastatin (ROS), atorvastatin (ATO), simvastatin (SIM), pravastatin (PRA) and fluvastatin (FLU). Initial doses were 10 mg for ROS, ATO and SIM, 20 mg for PRA, and 40 mg for FLU. Patients who failed to reach the target cholesterol level with the initial dosage where titrated to the next highest dosage (20 and 40 mg for ROS and PRA, 20, 40 and 80 mg for ATO and SIM, and 40 and 80 mg for FLU). Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study

2006 NHS Economic Evaluation Database.